IP Library › Granted Patent US 12,697,310
Granted Patent B2
US 12,697,310 · App. 17/816,980 · Granted Aug 4, 2026

Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles

Inventors: Richard M Lopachin (New Rochelle, NY); Terrence Gavin; Brian Geohagen (Bronx, NY)
Assignee: MONTEFIORE MEDICAL CENTER
A61K31/12A01N1/126A61K31/095A61K31/167A61K31/36A61K31/381A61K31/402A61K31/495A61K31/5375A61P39/06C07C49/80C07C49/807C07C49/825C07C49/84C07C233/33C07C323/22C07D207/04C07D207/325C07D295/112C07D333/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,697,310
App. No.
17/816,980
Filed
Aug 2, 2022
Granted
Aug 4, 2026
Kind
B2
Art Unit
1626
USPC
514/231.2
Abstract

Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.

Claims (26)

1 . A method of treating a toxicity due to a therapeutic agent or an agent that causes oxidative cellular damage in a subject receiving the agent, the method comprising administering to the subject a compound of formula (I)

or a tautomer thereof; or a geometric or optical isomer thereof; or racemate thereof; or a pharmaceutically acceptable salt thereof, in an amount effective to reduce the toxicity due to the agent,

wherein:

R 1 and R 3 are independently alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heteroaryl, heteroaralkyl or heterocycloalkyl;

R 2 is NH 2 , NHCOR 3 , NH-alkyl, N,N-dialkyl, cyclic N,N-di alkyl, SH, S-alkyl, S-aryl, aryl, heteroaryl, or NR 4 R 5 ; and

R 4 and R 5 are independently alkyl or NH-alkyl, or R 4 and R 5 can form a ring with each other, and any ring so formed is heteroaromatic, and any ring so formed may contain one or more N, O and/or S atoms;

wherein any aryl, aralkyl, cycloalkyl, heteroaryl, heteroaralkyl, or heterocycloalkyl ring can be independently substituted with ═O, OH, halogen, CH 3 or NH 2 ; and

wherein any alkyl can independently be branched or unbranched.

2 . The method of claim 1 , wherein the therapeutic agent is acetaminophen, diclofenac, cyclophosphamide, valproic acid, clopidogrel, esomeprazole, atorvastatin, duloxetine, raloxifene, a platinum containing antineoplatstic agent, or radiation used in radiation therapy.

3 . The method of claim 2 , wherein the platinum containing antineoplatstic agent is cisplatin.

4 . The method of claim 1 , wherein the agent that causes oxidative cellular damage is tobacco smoke, acrolein, alcohol, or a radiocontrast agent.

5 . The method of claim 1 , wherein the agent is a polarizable electrophile.

6 . The method of claim 1 , wherein the toxicity is hepatotoxicity, neurotoxicity, or toxicity due to oxidative cellular stress.

7 . The method of claim 1 , wherein the compound of formula (I) and the agent are administered to the subject at the same time.

8 . The method of claim 7 , wherein the compound of formula (I) and the agent are administered in the same formulation.

9 . The method of claim 1 , wherein the compound of formula (I) is administered to the subject before administration of the agent to the subject.

10 . The method of claim 1 , wherein the compound of formula (I) is administered to the subject after administration of the agent to the subject.

11 . The method of claim 1 , wherein the compound of formula (I) is administered by parenteral administration.

12 . The method of claim 1 , wherein the compound of formula (I) is formulated with an enteric coating and the compound is administered orally.

13 . The method of claim 1 , wherein the compound of formula (I) prevents or reduces hepatotoxicity.

14 . The method of claim 1 , wherein:

R 1 is alkyl, cycloalkyl, or

R 2 is NH 2 , NHCOR 3 , NH-alkyl, SH, S-alkyl, S-aryl or

wherein R 6 is hydrogen or alkyl.

15 . The method of claim 1 , wherein the compound of formula (I) is:

or a tautomer thereof; or a geometric or optical isomer thereof; or racemate thereof; or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2023
From: LOPACHIN, RICHARD M.; GAVIN, TERRENCE
To: MONTEFIORE MEDICAL CENTER
Reel/Frame 064988/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2023
From: GEOHAGEN, BRIAN
To: MONTEFIORE MEDICAL CENTER
Reel/Frame 065016/0477 →
Continuity (3)
Continuation 15735214 · Jun 27, 2016
Provisional Application 62185801 · Jun 29, 2015
Related Publication 20230133011A1 · May 4, 2023
References Cited (63)
US 5877210A · Schieven · 1999 [cited by applicant]
US 8034838B2 · Thompson et al. · 2011 [cited by applicant]
US 8835510B2 · LoPachin et al. · 2014 [cited by applicant]
US 10104882B2 · LoPachin · 2018 [cited by examiner]
US 11413255B2 · LoPachin · 2022 [cited by examiner]
US 20080139496A1 · Prendergast · 2008 [cited by applicant]
US 20080254130A1 · Gupta · 2008 [cited by applicant]
US 20130116337A1 · LoPachin et al. · 2013 [cited by applicant]
US 20130267474A1 · Seeram et al. · 2013 [cited by applicant]
US 20160074339A1 · LoPachin et al. · 2016 [cited by applicant]
US 20220016051A1 · Lopachin · 2022 [cited by examiner]
WO 0220500A2 · 2002 [cited by applicant]
WO 2011156181A1 · 2011 [cited by applicant]
WO 2014179187A1 · 2014 [cited by applicant]
Ferreira, E. A., E. Gris, K. Felipe, J. Correia, E. Cargnin-Ferreira, D. Filho and R. Pedrosa, “Potent hepatoprotective effect in CCI4-induced hepatic injury in mice of phloroacetophenone from Myrcia multiflora”, Libyan… [cited by examiner]
LoPachin, R., T. Gavin, B. Geohagen, L. Zhang, D. Casper, R. Lekhraj and D. Barber, “β-Dicarbonyl enolates: a new class of neuroprotectants”, J. Neurochem. (2011), 116, pp. 132-143. (Year: 2010). [cited by examiner]
Allegretti, P., M. de las Mercedes Schiavoni, E. Castro and J. Furlong, “Tautomeric Equilibria Studies by Mass Spectrometry”, World Journ. Chem. (2007), 2 (2), pp. 25-62. (Year: 2007). [cited by examiner]
Bentes et al., Structure of dihydrochalcones and related derivatives and their scavenging and antioxidant activity against oxygen and nitrogen radical species. Molecules 16: 2011, 1749-1760. [cited by applicant]
Brenn et al., (2014) St. John's Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein. Brain Pathol 24: 1824. Epub Jun. 28, 2013. [cited by applicant]
Chang et al., “Antiplatelet effect of phloroglucinol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production.” Toxicol App Pharmacol 263: 2012, 287-295. [cited by applicant]
Chassany et al., “Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethyphloroglucinol—a randomized double-blind, placebo-controlled study.” 2007, Aliment Pharmacol. 25: 1115-1123. [cited by applicant]
Chen et al., “Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation.” Chem Res Toxicol 15: 2002, 907-914. [cited by applicant]
Dinamarca et al., “Hyperforin prevents B-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-b-deposits.” 2006, Mole Physch. 11: 1032-1048. [cited by applicant]
Ferreira et al., “Potent hepatoprotective effect in CC14-induced hepatic injury in mice of phloroacetophenone from Myrcia multiflora.” Libyan J Med 5: 4891-4896. 2010. [cited by applicant]
Galati et al., “Potential toxicity of flavonoids and other dietary phenolics: significance for the chemopreventive and anticancer properties.” Free Rad. Biol. Med 37: 287-303. 2004. [cited by applicant]
Geohagen et al., “Enolate-Forming Phloretin Pharmacophores: Hepatoprotection in an Experimental Model of Drug-Induced Toxicity.” J Pharmacol. Exp. Ther. 357, epub 2016. [cited by applicant]
Griffith et al., “Neurobiological effects of hyperforin and its potential in Alzheimer's disease therapy.” Curr Ivfed Chem 17: 391-406. 2010. [cited by applicant]
Harsanyi et al., “2,6-Dihydroxy-4-Pyrrolidinyl-Acetophenone and Its Complex With Pyrrolidine.” Heterocyc. Comm. 2002, 8(3), pp. 255-258. [cited by applicant]
Hatcher et al., “Curcumin: from ancient medicine to current clinical trials.” Cell Mal. Life Sci. 65: 1631-1652. 2008. [cited by applicant]
Head, E., “Oxidative damage and cognitive dysfunction: antioxidant treatments to promote healthy brain aging.” Neurochem. Res. 34: 670-678. 2009. [cited by applicant]
International Search Report and Written Opinion mailed Nov. 4, 2016 in International Patent Application No. PCT/US16/39487, 12 pages. [cited by applicant]
Iqbal et al., “Alzheimer's disease: a multifunctional disorder seeking multitherapies.” Alzheimer & Dementia 6: 420-424. 2010. [cited by applicant]
Jaeschke et al., “Caveats of using acetaminophen hepatotoxicity models for natural product testing.” Tax Letters 215: 40-41. 2012. [cited by applicant]
Kamat et al., “Antioxidants in central nervous system diseases: preclinical promise and translational challenges.” J Alzheimers Dis. 15: 473-493. 2008. [cited by applicant]
Kim et al., “Effect of phloroglucinol on oxidative stress and inflammation.” Food Chem Toxicol 48: 2925-2933. 2010. [cited by applicant]
Kim et al., “Phloroglucinol exerts protective effects against oxidative stress-induced cell damage in SH-SY5Y cells.” J Pharmacol Sci 119: 186-192. 2012. [cited by applicant]
Kung et al. “Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.” Bioorg. Med. Chem. Lett. 18 (2008) pp. 6273-6278. [cited by applicant]
Lambert et al., Possible controversy over dietary polyphenols: benefits vs risks. Chem Res Toxicol 20: 583-585. 2007. [cited by applicant]
Lopachin et al., “Application of the hard and soft acids and bases (HSAB) theory to toxicant-target interactions.” Chem Res Toxicol 25: 239-251. 2012. [cited by applicant]
Lopachin et al., “B-Dicarbony 1 enolates: a new class of neuroprotectants.” J Neurochem 116: 132-143. 2011. [cited by applicant]
Lopachin et al., “Molecular mechanisms of aldehyde toxicity: a chemical perspective.” Chem. Res. Toxicol. 27, 1081-1091. 2014. [cited by applicant]
Mammino, L., “Investigation of the antioxidant properties of hyperjovinol A through its Cu(II) coordination ability.” J A1olModel 19: 2127-2142. 2013. [cited by applicant]
Mathiesen et al., “Hydrogen bond formation as basis for radical scavenging activity: a structure-activity study of C-methylated dihydrochalcones from Myrica gale and structurally related acetophenones.” Free Rad Biol Me… [cited by applicant]
Piao et al., “Phloroglucinol inhibits ultraviolet B radiation-induced oxidative stress in the mouse skin.” Int J Rad Biol. 2014. [cited by applicant]
Piyachaturawat et al., “Evaluation of the acute and subacute toxicity of a choleretic phloracetophenone in experimental animals.” Toxic. Lett. 129, pp. 123-132, 2002. [cited by applicant]
Rezk et al., “The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids.” Biochem Biophys Res Comm. 295: 9-13. 2002. [cited by applicant]
Ryu et al., “Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing Nrf2 activity.” PLoS One 8: e71178. 2013. [cited by applicant]
Sappington et al., “The ethyl pyruvate analogues, diethy oxaloproprionate, 2-acetamidoacrylate, and methyl-2-acetamidoacrylate, exhibit anti-inflammatory properties in vivo and/or in vitro.” BiochemPharmacol 70, 1579-15… [cited by applicant]
Schaefer et al., “Polyphenolic apple juice extracts and their major constituents reduce oxidative damage in human colon cell lines.” Mol. Nutr. Food Res. 2006, 50, pp. 24-33. [cited by applicant]
Singh et al., “Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism and cellular and molecular mechanisms.” J Agric Food Chem 56: 4855-4873. 2008. [cited by applicant]
Singh et al., “Phloroglucinol compounds of therapeutic interest: global patent and technology status.” Exp Opin. Ther Patents 19: 847-866.2009. [cited by applicant]
Singh et al., “Phlororglucinol compounds of natural origin.” Nat. Prod. Rep. 23: 558-591. 2006. [cited by applicant]
So et al., “Phloroglucinol attenuates free radical-induced oxidative stress.” Prev Nutr Food Sci 19: 129-135. 2014. [cited by applicant]
STN Registry database entry: CAS RN 100942-39-0 (Entered STN: Mar. 22, 1986). [cited by applicant]
STN Registry database entry: CAS RN 1610500-76-9 (Entered STN: Jun. 11, 2014). [cited by applicant]
STN Registry database entry: CAS RN 206194-38-9 (Entered STN: Jun. 2, 1998). [cited by applicant]
STN Registry database entry: CAS RN 266338-15-2 (Entered STN: May 24, 2000). [cited by applicant]
STN Registry database entry: CAS RN 404011-08-1 (Entered STN: Apr. 4, 2002). [cited by applicant]
Tyrell et al., “The synthesis and anticancer effects of a range of natural and unnatural hop B-acids on breast cancer cells.” Phytochemistry Letters 5 (2012), pp. 144-149. [cited by applicant]
Wurglics et al., “Hepericum perforatum: a modem herbal antidepressant: pharmacokinetics of active ingredients.” Clin Pharmacokinet 45: 449-468. 2006. [cited by applicant]
Youdim et al., “A possible emergmg role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects.” Free Rad Biol. Med. 30: 583-594. 2001. [cited by applicant]
Zanoli, P., “Role of hyperforin in the pharmacological activities of St. John's Wort.” CNS Drug Rev. 10: 203-218. 2004. [cited by applicant]
Zhu et al., “In vitro attenuation of acrolein-induced toxicity by phloretin, a phenolic compound from apple.” Food Chem. 135: 1762-1768. 2012. [cited by applicant]